Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Nature Neuroscience|December 6, 2011
miR-124 acts through CoREST to control onset of Sema3A sensitivity in navigating retinal growth conesMarie-Laure Baudet, Krishna H Zivraj, Cei Abreu-Goodger, et al.Plos One|May 5, 2017
Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patientsElza C de Bruin, Jessica L Whiteley, Claire Corcoran, et al.BMJ Open Gastroenterology|March 26, 2022
Metabolic dysfunction-related liver disease as a risk factor for cancerAlasdair Taylor, Moneeza K Siddiqui, Philip Ambery, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 18, 2025
A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated SteatohepatitisJavier Armisen, Armando Flor, John Eriksson, et al.JAMA Cardiology|December 16, 2020
Assessing the Role of Rare Genetic Variation in Patients With Heart FailureGundula Povysil, Olympe Chazara, Keren J Carss, et al.The Journal of Pathology|February 19, 2015
Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumoursJeffrey C Francis, Lorenzo Melchor, James Campbell, et al.Science Translational Medicine|August 28, 2015
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancerIsaac Garcia-Murillas, Gaia Schiavon, Britta Weigelt, et al.Nature|May 7, 2013
The shaping and functional consequences of the microRNA landscape in breast cancerHeidi Dvinge, Anna Git, Stefan Gräf, et al.Scientific Data|March 2, 2017
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cellsStephen J Pettitt, Dragomir B Krastev, Helen N Pemberton, et al.Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.Pageof 3